Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood

Vinge has advised Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood Grupp OÜ (“Combiwood”).
May 22, 2025

Vinge has advised the FEA Group, which includes Freys Hyrverk and Stockholm Limousine Service, in connection with its merger with Inclusion Services International

The merger strengthens the new FEA Group’s capacity and service offering, which includes everything from comprehensive travel planning and hotel bookings to security-classified passenger transport and risk assessments. According to management, the newly formed group will have a unique position in the Swedish market with the opportunity to introduce new transport and security solutions that are currently unmatched in the country.
May 21, 2025

Vinge advises EHF Invest on its public offer for Real Fastigheter

EHF Invest AB has made a public offer for all shares in Real Fastigheter AB (publ).
May 21, 2025